2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
Blood
Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia
PLOS One
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research | AACR
Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma
Nature | Leukemia
Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche
Nature | Leukemia
Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation
Blood Advances | American Society of Hematology
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
British Journal of Hematology
Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
Nature Communications
Current use of monoclonal antibodies in the treatment of multiple myeloma
British Journal of Hematology
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
Molecular Cancer Therapeutics | AACR
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression
Journal of Clinical Investigation
Targeting MYC in multiple myeloma
Leukemia | Nature
Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Clinical Cancer Research| AACR
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Nature Reviews | Clinical Oncology
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
Blood
Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia
PLOS One
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research | AACR
Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma
Nature | Leukemia
Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche
Nature | Leukemia
Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation
Blood Advances | American Society of Hematology
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
British Journal of Hematology
Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
Nature Communications
Current use of monoclonal antibodies in the treatment of multiple myeloma
British Journal of Hematology
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
Molecular Cancer Therapeutics | AACR
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression
Journal of Clinical Investigation
Targeting MYC in multiple myeloma
Leukemia | Nature
Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Clinical Cancer Research| AACR
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Nature Reviews | Clinical Oncology